Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Holzman

Ophthalmology Mc Lean, VA Medical Doctor

NPI 1003085093 CMS profile 562320

1750 Tysons Blvd Ste 120, Mc Lean, VA 22102

Open in the dashboard

General payments

$4,738

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Holzman of Mc Lean, VA is reported in the CMS Open Payments database as having received $4,738 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,082 23
2024 General $621 15
2023 General $911 12
2022 General $709 17
2021 General $625 21
2020 General $517 20
2019 General $272 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Holzman
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Andrew Holzman were reported at $1,082. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Andrew Holzman Ophthalmology median Middle half National median
2019 $272 $258 $104–$655 $163
2020 $517 $126 $45–$321 $114
2021 $625 $205 $76–$534 $132
2022 $709 $266 $100–$678 $149
2023 $911 $308 $117–$745 $160
2024 $621 $340 $127–$846 $164
2025 $1,082 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,800 25 payments
  2. Glaukos Corporation $1,078 18 payments
  3. Kala Pharmaceuticals, Inc. $675 25 payments
  4. Harrow Eye, LLC $248 6 payments
  5. Sun Pharmaceutical Industries Inc. $193 11 payments
  6. Bausch & Lomb Americas Inc. $125 6 payments
  7. Oyster Point Pharma, Inc. $119 5 payments
  8. Eyevance Pharmaceuticals LLC $104 5 payments
  9. Novartis Pharmaceuticals Corporation $103 5 payments
  10. Dompe US, Inc. $102 3 payments
  11. Other $189 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,738 116 payments
Products named General payments · program years 2019–2025
  1. INVELTYS $556 24 payments
  2. EYSUVIS $542 19 payments
  3. WaveLight EX500 Excimer Laser $308 5 payments
  4. Photrexa Viscous and Photrexa $298 5 payments
  5. Wavelight Refractive Suite $290 3 payments
  6. VEVYE $248 6 payments
  7. KXL1B-CE-marked KXLsystem $226 3 payments
  8. Wavelight $213 4 payments
  9. Cequa $193 11 payments
  10. KXL system (not refurbished) $182 2 payments
  11. Other $1,929 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record